Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma

Table 2 Comparing key features of the LEGACY study and DOSISPHERE trial

	LEGACY	DOSISPHERE
Study design	Multi-center single-arm retrospective study	Multicenter randomized control phase ii trial
Objective	To assess clinical outcomes of Y-90 glass microsphere treatment in patients with unresectable solitary HCC lesions	To compare clinical outcomes of lobar TARE using 120 Gy (SDA) versus > 205 Gy (PDA) in patients with intermediate/advanced HCC
Inclusion criteria	Unresectable solitary lesions (≤ 8 cm); BCLC A or C (ECOG 0-1); Child-Pugh score A	≥ 1 unresectable lesion ≥ 7 cm; BCLC A, B, or C
Exclusion criteria	Patients with vascular or extrahepatic disease, significant ascites, encephalopathy, or prior LRT, LT, resection, or systemic therapy	Patients with micro-aggregate albumin (MAA) studies demonstrating poor tumor targeting
Overall survival	At 3 yr, 86.6% for patients treated with TARE alone (median dose 410 Gy) and 92.8% for patients who down-staged via TARE	Overall survival was improved in the personalized dosimetry group (26.6 mo vs 10.7 mo)
Downstaging	21% successfully down-staged to LT; 6.8% to resection.	36% patients in the PDA group and 3.5% (1/28) in the SDA group down-staged to resection1

¹Including patients with portal vein tumor thrombus.

HCC: Hepatocellular carcinoma; BCLC: Barcelona clinic liver criteria; LRT: Locoregional therapy; LT: Liver transplant; PDA: Personalized dosimetry group; SDA: Standardized dosimetry group; TARE: Transarterial radio-embolization.